- Home
- LXRX vs BME Comparison
LXRX vs BME Comparison
Compare LXRX & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- BME
- Stock Information
- Founded
- LXRX 1995
- BME 2005
- Country
- LXRX United States
- BME United States
- Employees
- LXRX N/A
- BME N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- BME Trusts Except Educational Religious and Charitable
- Sector
- LXRX Health Care
- BME Finance
- Exchange
- LXRX Nasdaq
- BME Nasdaq
- Market Cap
- LXRX 552.4M
- BME 486.1M
- IPO Year
- LXRX 2000
- BME N/A
- Fundamental
- Price
- LXRX $1.38
- BME $38.36
- Analyst Decision
- LXRX Buy
- BME
- Analyst Count
- LXRX 5
- BME 0
- Target Price
- LXRX $3.23
- BME N/A
- AVG Volume (30 Days)
- LXRX 2.4M
- BME 34.0K
- Earning Date
- LXRX 11-06-2025
- BME 01-01-0001
- Dividend Yield
- LXRX N/A
- BME 6.26%
- EPS Growth
- LXRX N/A
- BME N/A
- EPS
- LXRX N/A
- BME 1.44
- Revenue
- LXRX $58,432,000.00
- BME N/A
- Revenue This Year
- LXRX $66.55
- BME N/A
- Revenue Next Year
- LXRX N/A
- BME N/A
- P/E Ratio
- LXRX N/A
- BME $28.37
- Revenue Growth
- LXRX 1504.83
- BME N/A
- 52 Week Low
- LXRX $0.28
- BME $35.53
- 52 Week High
- LXRX $1.95
- BME $43.20
- Technical
- Relative Strength Index (RSI)
- LXRX 49.80
- BME 62.21
- Support Level
- LXRX $1.30
- BME $37.98
- Resistance Level
- LXRX $1.48
- BME $38.56
- Average True Range (ATR)
- LXRX 0.07
- BME 0.37
- MACD
- LXRX -0.02
- BME 0.00
- Stochastic Oscillator
- LXRX 27.77
- BME 83.26
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.